ENOV · Enovis CORP
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Apr 5, 2022; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (non-GAAP) non-GAAP | $207.9M | Six Months Ended July 3, 2026 | — |
|
|
|||
| Adjusted EBITDA margin (non-GAAP) non-GAAP | 17.7% | Six Months Ended July 3, 2026 | — |
|
|
|||
| Adjusted gross profit (Non-GAAP) non-GAAP | $725.9M | Six Months Ended July 3, 2026 | — |
|
|
|||
| Adjusted gross profit margin (Non-GAAP) non-GAAP | 61.9% | Six Months Ended July 3, 2026 | — |
|
|
|||
| Adjusted net earnings per diluted share non-GAAP | $0.9 | second quarter 2026 | — |
| Adjusted net income from continuing operations (non-GAAP) non-GAAP | $103.8M | Six Months Ended July 3, 2026 | — |
|
|
|||
| Adjusted net income margin from continuing operations non-GAAP | 8.9% | Six Months Ended July 3, 2026 | — |
| Adjusted net income per share - diluted from continuing operations (non-GAAP) non-GAAP | $1.79 | Six Months Ended July 3, 2026 | — |
|
|
|||
| P&R net sales growth on an organic basis non-GAAP | 3% | second quarter 2026 | — |
| Recon net sales growth on a reported basis | 8% | second quarter 2026 | — |
| Recon net sales growth on an organic basis non-GAAP | 6% | second quarter 2026 | — |
| Second-quarter sales growth on a reported basis | 3% | Second-quarter 2026 | — |
| Second-quarter sales growth on an organic basis non-GAAP | 5% | Second-quarter 2026 | — |
| Adjusted net income per share - diluted from continuing operations non-GAAP | $0.89 | Three Months Ended April 3, 2026 | — |
|
|
|||
| Adjusted diluted earnings per share non-GAAP | $3.3 | Full Year 2025 | — |
| Adjusted earnings per diluted share non-GAAP | $0.95 | Q4 2025 | — |
| Organic Growth Rate | 5.9% | Year Ended December 31, 2025 | — |
| Organic sales growth non-GAAP | 6% | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENOV
this stock
Enovis CORP
|
$1.43B | -6.5% | +6.7% | — | 15.1% |
|
ABT
Abbott Laboratories
|
$195.90B | -10.2% | +5.7% | 31.5 | 1.2% |
|
SYK
Stryker Corp
|
$127.12B | -5.9% | +11.2% | 34.3 | 1.8% |
|
MDT
Medtronic plc
|
$115.17B | -5.0% | +8.4% | 24.1 | 1.1% |
|
BSX
Boston Scientific Corp
|
$67.88B | -50.9% | +12.5% | 19.0 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Apr 5, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENOV | -4.5% | -14.6% | +1.0% | -14.6% | -6.5% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -4.9% | -17.6% | -12.5% | -17.6% | -19.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.